FO
ARCT icon

FT Options’s Arcturus Therapeutics ARCT Stock Holding History

FT Options’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,857
Closed -$3K – 257
2016
Q3 		$3K Buy
+2,857
New +$92.3K ﹤0.01% 335

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

FT Options's ARCT Position: Q4 2016 in Review

FT Options sold out of Arcturus Therapeutics (ARCT) in Q4 2016, closing a stake of 2 shares.

FT Options first reported a position in ARCT in Q3 2016 and held it in 1 quarter. The position peaked at $0 in Q3 2016. 42 funds tracked by Wall St. Rank hold ARCT as of Q4 2016.

  • FT Options reported no remaining Arcturus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • FT Options sold 2 Arcturus Therapeutics shares in Q4 2016.
  • FT Options first reported a position in Arcturus Therapeutics in Q3 2016 and held it in 1 quarter.
  • FT Options's Arcturus Therapeutics position peaked at $0 in Q3 2016.
  • 42 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2016.

Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.